AACR21: Eli Lil­ly blazes new trail for RET in­hibitor, gin­ning up a re­sponse in 9 sol­id tu­mor types in ear­ly da­ta

Eli Lil­ly was first to mar­ket with its RET fu­sion-in­hibitor Retev­mo in May, stak­ing its claim in the rare tu­mor in­di­ca­tion. But Roche wasn’t far on its heels with an ap­proval of its own for RET in­hibitor Gavre­to, and now Lil­ly is look­ing to get the leg up on its clos­est com­peti­tor.

Lil­ly’s Retev­mo post­ed a 47% ob­jec­tive re­sponse rate with re­spons­es in nine unique RET fu­sion-pos­i­tive tu­mor types, ac­cord­ing to ear­ly da­ta from the Phase I/II LI­BRET­TO-001 un­veiled Sun­day at the vir­tu­al AACR meet­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER